Special Issue

Bioavailability and Bioequivalence Assessment of Topical Drug Products Intended for Local Action

Message from the Guest Editors

Demonstrating bioequivalence (BE) for topical generics remains challenging due to the lack of standardized methods beyond the FDA's vasoconstrictor assay (VCA). While clinical endpoint studies are often required, recent advances focus on surrogate approaches like tape stripping, microdialysis, and in vitro tests (IVRT/IVPT). Regulatory emphasis on Q1/Q2/Q3 sameness further supports alternative BE strategies. This Special Issue on the bioavailability (BA) and bioequivalence (BE) of topical formulations intended for local action will focus on research and review papers discussing applications of validated methods used to assess the BE of topical dosage forms not intended for absorption (i.e., excluding transdermal dosage forms) and will include both in vivo and in vitro methods. We welcome articles dealing with all aspects of the BA/BE of topical dosage forms for local action, and invite researchers and drug developers to submit their original research or review articles with expert opinions and perspectives in this area.

Guest Editors

Prof. Dr. Isadore Kanfer

- 1. Leslie Dan College of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada
- 2. Faculty of Pharmacy, Rhodes University, Makhanda, South Africa

Dr. Seeprarani Rath

Center For Dermal Research, Rutgers, The State University of New Jersey, 145 Bevier Rd, Piscataway, NJ 08854, USA

Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/241356

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

